DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
MEDI4736 is an investigational drug.
There have been 297 clinical trials for MEDI4736. The most recent clinical trial was a Phase 2 trial, which was initiated on September 6th 2019.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and National Cancer Institute (NCI).
There are forty-five US patents protecting this investigational drug and nine hundred and twenty-one international patents.
Recent Clinical Trials for MEDI4736
|Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer||Arbeitsgemeinschaft Gynaekologische Onkologie Austria||Phase 2|
|Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer||Belgian Gynaecological Oncology Group||Phase 2|
|Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer||European Network of Gynaecological Oncological Trial Groups (ENGOT)||Phase 2|
Top disease conditions for MEDI4736
Top clinical trial sponsors for MEDI4736
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|MEDI4736||Get Started for $10||Synergistic combination of immunologic inhibitors for the treatment of cancer||The University of Chicago (Chicago, IL)||Get Started for $10|
|MEDI4736||Get Started for $10||Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy||MedImmune Limited (Cambridge, GB)||Get Started for $10|
|MEDI4736||Get Started for $10||Heterocyclic modulators of lipid synthesis||3-V Biosciences, Inc. (Menlo Park, CA)||Get Started for $10|
|MEDI4736||Get Started for $10||Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer||AstraZeneca AB (Sodertalje, SE)||Get Started for $10|
|MEDI4736||Get Started for $10||Apilimod for use in the treatment of renal cancer||LAM Therapeutics, Inc. (Guilford, CT)||Get Started for $10|
|MEDI4736||Get Started for $10||Anti-B7 H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer||MEDIMMUNE, LLC (Gaithersburg, MD)||Get Started for $10|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|MEDI4736||Canada||CA2889182||2032-10-26||Get Started for $10|
|MEDI4736||European Patent Office||EP2911669||2032-10-26||Get Started for $10|
|MEDI4736||World Intellectual Property Organization (WIPO)||WO2014066834||2032-10-26||Get Started for $10|
|MEDI4736||Australia||AU2015276173||2034-06-17||Get Started for $10|
|MEDI4736||Australia||AU2020210207||2034-06-17||Get Started for $10|
|MEDI4736||Brazil||BR112016028964||2034-06-17||Get Started for $10|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|